New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 2, 2008, Pages 84-91

  Viljoen, Adie ^a   Wierzbicki, Anthony S ^b  

^a LISTER HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Cholesterol; Drug; Inflammation; Novel therapy; Nutrition; Patent

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACYL COENZYME A DESATURASE; AMANTADINE DERIVATIVE; APOLIPOPROTEIN; APOLIPOPROTEIN A1 MILANO; ARACHIDONATE 5 LIPOXYGENASE; BILE ACID SEQUESTRANT; BIOLOGICAL MARKER; CHOLESTEROL; COLESEVELAM; CSL 111; CYCLOHEXANE DERIVATIVE; D4F; ETC 216; FIBRIC ACID DERIVATIVE; HETEROCYCLIC COMPOUND; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; NEW DRUG; NUCLEAR FACTOR; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PEPTIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; POLYMER; PROTEIN DERIVATIVE; PURINERGIC RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT;

ADD ON THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET; DIET SUPPLEMENTATION; DRUG DESIGN; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PATENT; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT; BLOOD; DIAGNOSTIC TEST; METABOLIC SYNDROME X; PROGNOSIS;

ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIAGNOSTIC TESTS, ROUTINE; DIETARY SUPPLEMENTS; DRUG DESIGN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X; PATENTS AS TOPIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 51149094821     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008784705313     Document Type: Review

References (97)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064): 1498-1504.
2. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360(9326): 2-3.
3. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357(15): 1477-1486.
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364(9438): 937-952.
5. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356(23): 2388-2398.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
7. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-239.
8. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 1987; 59(14): 91G-94G.
9. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation in patients without diabetes. J Cardiovasc Risk 2002; 9: 183-190
10. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): A potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45(12): 1609-1616.
11. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol 2004; 59(5): 479-484.
12. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95(1): 76-82.
13. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004; 53(4): 1068-1073.
14. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: An overview. Biomarkers 2005; 10(Suppl 1): S10-S23.
15. Patrono C, Falco A, Davi G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 2005; 5(2): 198-203.
16. Holvoet, P. N., Collen, D.: US20077229775 (2007).
17. Holvoet, P,N., Collen, D.: US20077229776 (2007).
18. Holvoet, P.N., Collen, D.J.: US20076727102 (2007).
19. Engstrom G, Hedblad B, Janzon L, et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: A population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007; 14(3): 392-397.
20. Bihain BE, Yen FT. The lipolysis stimulated receptor: A gene at last. Curr Opin Lipidol 1998; 9(3): 221-224.
21. Bihain, B., Bougueleret, L., Yen-Potin, F.: US20077220722 (2007).
22. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the. PREMIER clinical trial. JAMA 2003; 289(16): 2083-2093.
23. Appel LJ, Sacks FM, Carey VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 2005; 294(19): 2455-2464.
24. Mitka M. DASH dietary plan could benefit many, but few hypertensive patients follow it. JAMA 2007; 298(2): 164-165.
25. Dirks AJ, Leeuwenburgh C. Caloric restriction in humans: Potential pitfalls and health concerns. Mech Ageing Dev 2006; 127(1): 1-7.
26. Ramirez, M.B., Angles, L.M.N., Reguant, M.J.: WO07063158A2 (2007).
27. John S, Sorokin AV, Thompson PD. Phytosterols and vascular disease. Curr Opin Lipidol 2007; 18(1): 35-40.
28. Katan MB, Grundy SM, Jones P, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003; 78(8): 965-978.
29. Glueck CJ, Gordon DJ, Nelson JJ, et al. Dietary and other correlates of changes in total and low density lipoprotein cholesterol in hypercholesterolemic men: The lipid research clinics coronary primary prevention trial. Am J Clin Nutr 1986; 44(4): 489-500.
30. Platt, D., Pelled, D., Shulman, A.: NZ0541887A (2007).
31. Burnett JR, Huff MW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin Investig Drugs 2006; 15(11): 1337-1351.
32. Brouwer IA, Geelen A, Katan MB. n-3 Fatty acids, cardiac arrhythmia and fatal coronary heart disease. Prog Lipid Res 2006; 45(4): 357-367.
33. Burr ML, Fehily AM, Gilbert JF, et al. Effects uf changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989; 2(8666): 757-761.
34. Ness AR, Hughes J, Elwood PC, et al. The long-term effect of dietary advice in men with coronary disease: Follow-up of the Diet and Reinfarction trial (DART). Eur J Clin Nutr 2002; 56(6): 512-518.
35. Burr ML. Secondary prevention of CHD in UK men: The diet and reinfarction trial and its sequel. Proc Nutr Soc 2007; 66(1): 9-15.
36. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardio. Lancet 1999; 354(9177): 447-455.
37. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentacnoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369(9567): 1090-1098.
38. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: A randomized controlled trial. JAMA 2005; 293(23): 2884-2891.
39. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: The study on omega-3 fatty acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006; 295(22): 2613-2619.
40. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99(1): 95-112.
41. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-1278.
42. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371(9607): 117-125.
43. Kidd J. Life after statin patent expiries. Nat Rev Drug Discov 2006; 5(10): 813-814.
44. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
45. Libby P. The forgotten majority: Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005; 46(7): 1225-1228.
46. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: A meta-analysis. Clin Ther 2006; 28(1): 26-35.
47. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81(4A): 66B-69B.
48. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92(2): 152-160.
49. Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol 2004; 15(4): 387-392.
50. Maitland-van der Zee AH, Boerwinkle E. Pharmacogenetics of response to statins: Where do we stand? Curr Atheroscler Rep 2005; 7(3): 204-208.
51. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338(2): 86-93.
52. Winkelmann BR, Hoffmann MM, Nauck M, et al. Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J 2003; 3(5): 284-296.
53. Miettinen TA, Kesaniemi YA. Cholesterol absorption: Regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989; 49(4): 629-635.
54. Cohen JC, Pertsemlidis A, Fahmi S, et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA 2006; 103(6): 1810-1815.
55. Wierzbicki AS. Lipid-altering agents: The future. Int J Clin Pract 2004; 58(11): 1063-1072.
56. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 2002; 90(2): 139-143.
57. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: A meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006; 17(6): 631-636.
58. Wierzbicki AS. Raising HDL-C: Back to the future? Int J Clin Pract 2007; 61(7): 1069-1071.
59. Wierzbicki AS. Intervening on HDL-C: Is it possible? Does it work? Int J Clin Pract 2007; 61(11): 1782-1786.
60. Franceschini G, Sirtori CR, Capurso A, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980; 66(5): 892-900.
61. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994; 90(4): 1935-1941.
62. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: The Limone sul Garda study. Circulation 2001; 103(15): 1949-1954.
63. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290(17): 2292-2300.
64. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007; 297(15): 1675-1682.
65. Oda, M.N., Forte, T.M.: US20077223726 (2007).
66. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the anti-oxidant enzyme, paraoxonase-1. Clin Sci (Lond) 2004; 37(12): 1986-94.
67. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005; 16(4): 393-399.
68. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: Potential for therapeutic intervention. Am J Cardiovasc Drugs 2004; 4(4): 211-217.
69. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001; 42(4): 545-552.
70. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-1 mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105(3): 290-292.
71. Fogelman, A.M., Navab, M.: EP1496930 (2005).
72. Datta G, Chaddha M, Hama S, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001; 42(7): 1096-1104.
73. Li X, Chyu KY, Faria N Jr, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110(12): 1701-1705.
74. Mahley RW, Rall SC Jr. Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-537.
75. Reddy ST, Anantharamaiah GM, Navab M, et al. Oral amphipathic peptides as therapeutic agents. Expert Opin Investig Drugs 2006; 15(1): 13-21.
76. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-1607.
77. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006; 21(1): 1-6.
78. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000; 355(9205): 675-687.
79. Dobrzyn A, Ntambi JM. The role of stearoyl-CoA desaturase in the control of metabolism. Prostaglandins Leukot Essent Fatty Acids 2005; 73(1): 35-41.
80. Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 2005; 6(2): 169-174.
81. WO07056846A1
82. Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006; 6(6): 606-614.
83. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007; 1771(8): 1065-1081.
84. Burke, S.K., Donovan, J.M.: US20077229613 (2007).
85. Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am J Cardiol 2007; 100(11 A): N15-n19.
86. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25(10): 2020-30.
87. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113(10): 1408-1418.
88. Pfahl, M., Tachdjian, C., Al-Shamma, HA., Fanjul, A.P., David, P.M., Spruce, L.W.: US20077226940 (2007).
89. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2-diabetes. Clin Ther 2007; 29(1): 74-83.
90. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007; 23(7): 1673-1684.
91. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): 868-874.
92. Del PF, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intimamedia thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46(7): 1111-1115.
93. Osher E, Weisinger G, Limor R, et al. The 5 lipoxygenase system in the vasculature: Emerging role in health and disease. Mol Cell Endocrinol 2006; 252(1-2): 201-206.
94. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: A randomized trial. JAMA 2005; 293(18): 2245-2256.
95. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002; 22(3): 364-373.
96. Caffrey, M., Ford, R., Pimm, A.: US20077227038 (2007).
97. Brocchini, S.J., Heller, J., Tomlinson, R., Duncan, R., Garrett, S., Klee, M.M.: US20077220414 (2007).